Introduction {#sec1-1}
============

Diabetes mellitus (DM) is characterized by chronic hyperglycemia and disturbances of carbohydrate, fat, and protein metabolism occurs due to deficiency of insulin (type 1) or insensitivity of the target tissues to insulin (type 2).\[[@ref1]\]

Several oral antidiabetic agents (ADAs) like metformin, sulfonylureas, meglitinides and Dipeptidyl peptidase 4 (DPP 4) inhibitors are currently available. Some of them increase the insulin secretion from pancreas, while others increase peripheral utilization of glucose by increasing the sensitivity of peripheral tissues to utilize glucose. Oral therapy for type 2 DM, when used appropriately, can safely assist patients to achieve glycemic target in the short term to medium term. Issues of safety and tolerability, notably change in weight, often limit the optimal application of antidiabetic drugs such as metformin and thiazolidinediones.\[[@ref2]\] Therefore, there is need for novel oral ADAs with different mechanisms of action from existing oral ADAs. Bromocriptine mesylate quick release formulation has been approved by *Food and Drug Administration* in May 2009 for the treatment of type 2 DM in adults as an adjunct to diet and exercise to improve glycemic control.\[[@ref3][@ref4]\] Treatment with dopamine agonist bromocriptine has been proposed as a mean to improve glucose and energy metabolism through activation of central nervous system (CNS) dopaminergic pathways responsible for metabolic control. This mechanism of action of bromocriptine tends to address hither to unexplored pathophysiology of hyperglycemia in type 2 DM. The pharmacological activity of bromocriptine occurs mainly through activation of D~2~ receptors and inhibition of D~1~ receptors in the CNS.\[[@ref5]\]

Current treatment guidelines recommend metformin as the first agent to be added to diet and lifestyle changes for the majority of patients. Metformin monotherapy is capable of lowering glycosylated hemoglobin (HbA~1C~) significantly and is generally well-tolerated with lower risk of hypoglycemia.\[[@ref6]\] A study conducted by Ramteke *et al*.,\[[@ref2]\] has showed bromocriptine is an effective and safe ADA which can be employed as monotherapy or in conjunction with metformin to achieve and maintain optimal glycemic control in Indian population. Against this backdrop, the present study was planned to compare effectiveness and safety of add on therapy of bromocriptine with metformin in Indian patients with type 2 DM.

Material and Methods {#sec1-2}
====================

It was a prospective, randomized, open-labeled phase IV clinical trial. The study was approved by the institutional ethics committee and conducted according to the Indian Council of Medical Research guidelines for Biomedical Research on Human Subjects, 2006, and the Declaration of Helsinki. Subjects were recruited in the diabetes outpatient department under the department of endocrinology of a tertiary care teaching hospital and the study was conducted between May and October 2012. The study was registered under Clinical Trials Registry-India (Registration Number-CTRI/2012/05/002659).

Based on an effect size of one, standard deviation of one, significance level α of 0.05 and power of the study as 80%, the target number of "evaluable" subjects was 20 per group. The sample size was calculated by using primer of biostatistics software (version 5.0). Considering a 20% drop out rate, this translated to a target recruitment of 25 subjects in each group.

Adults of either gender, aged between 18 and 60 and newly diagnosed cases (as per ADA guidelines)\[[@ref7]\] of type 2 DM with HbA~1C~ ≥ 6.5 and ≤ 10, were included in the study. Pregnant or lactating women, patients with FPG \> 250 mg/dL, PPPG \> 350 mg/dL, comorbid cardiovascular, renal and psychiatric complications, coadministration of drugs that were likely to interact with bromocriptine or metformin were excluded.

Patients, who fulfilled the selection criteria, were randomly allocated in three different treatment groups. Randomization was done by computer-generated randomization number. Patients in group A received metformin sustained release (SR) tablet (Lupin Diabetes Care Ltd., Mumbai, Maharashtra, India) 500 mg twice a day after food. Group B was treated with metformin 500 mg SR tablet twice a day after food plus bromocriptine mesylate (0.8 mg) quick release tablet(Lupin diabetes care Ltd., Mumbai, Maharastra, India) after breakfast. Group C was treated with metformin 500 mg SR tablet twice a day after food and bromocriptine (0.8 mg) quick release tablet after breakfast for first 7 days and thereafter continued to take two tablets for further treatment period. Compliance was assessed by pill count method at each follow-up visit and at the end of the study.

Clinical (body weight) and biochemical (FPG, PPPG) evaluation was done at baseline (day 0) and at subsequent follow-up visits on weeks 4, 8, and 12. HbA~1C~ estimation was done at baseline and at the end of treatment (12^th^ week).

Patients with worsening clinical conditions or rising plasma glucose level were withdrawn prematurely from the study. All patients were advised to stop smoking and consumption of alcohol during the study period. Patients were monitored continuously throughout the study for any adverse event (AE). Causality analysis of AE was done as per the World Health Organization-Uppsala Monitoring Centre (WHO-UMC) criteria.([@ref8])

 {#sec2-1}

### Statistical Analysis {#sec3-1}

Data were analyzed as per modified intention to treat (ITT) basis. Subjects reporting for at least one post-baseline follow-up visit were analyzed. All patients who were randomized were considered for safety analysis. Data were analyzed by repeated measures analysis of variance (ANOVA) and paired *t* test for intragroup comparison and by ANOVA for intergroup comparison. *Post hoc* analysis was done by Tukey\'s honestly significant difference (HSD) test. Categorical data in baseline demographic profile (gender) were analyzed by chi-square test. *P* value \< 0.05 was considered to be statistically significant.

Results {#sec1-3}
=======

Out of 80 patients screened, 74 were enrolled in the study. Out of 74 patients, 23 were treated with metformin 1000 mg/day (group A), 25 were treated with metformin 1000 mg/day and bromocriptine 0.8 mg/day (group B) and 26 were treated with metformin 1000 mg/day and bromocriptine 1.6 mg/day (group C). Out of 74 patients, 71 completed the study and 3 patients were lost to follow-up \[[Figure 1](#F1){ref-type="fig"}\]. The mean age of patients was 48.1, 52.6, and 49.3 years in the groups A, B, and C, respectively.

![The CONSORT 2010 flow diagram showing allocation, follow-up, and analysis subjects in groups A, B, and C](IJPharm-46-24-g001){#F1}

There was no statistically significant difference in the baseline HbA~1C~, FPG and PPPG levels \[[Table 1](#T1){ref-type="table"}\]. HbA~1C~ level significantly decreased in all three treatment groups at week 12 from their respective baseline values(*P* \< 0.05). Metformin alone and in combination with bromocriptine in escalating dose (0.8 mg/day and 1.6 mg/day) significantly (*P* \< 0.05) decreased FPG and PPPG levels at weeks 4, 8, and 12 compared with pretreatment values.

###### 

Baseline fasting plasma glucose, postprandial plasma glucose, and glycosylated hemoglobin levels (mean ± standard deviation) of groups A, B, and C. No statistically significant difference among groups A, B, and C in the baseline glycosylated hemoglobin, fasting plasma glucose, and postprandial plasma glucose levels. Data analyzed by analysis of variance

![](IJPharm-46-24-g002)

Intergroup analysis of data show at every interval (weeks 4, 8, and 12) add on therapy of bromocriptine with metformin compared with metformin alone significantly (*P* \< 0.05) decreased FPG and PPPG levels in a dose-dependent manner \[Figures [2](#F2){ref-type="fig"} and [3](#F3){ref-type="fig"}\]. At week 12, HbA~1C~ level in groups B and C significantly decreased compared with group A \[[Figure 4](#F4){ref-type="fig"}\]. Intergroup analysis did not show any statistically significant change in weight of study subjects at different intervals.

![Changes in fasting plasma glucose (FPG) level (mg/dL) in groups A, B, and C. FPG levels (mean± SD) in Group A are 155.7 ± 7.5, 142.7 ± 6.9, 124.8 ±11.2 at weeks 4,8, 12 respectively; in Group B are 145.1 ± 8.9, 131.2± 10.2, 105.6 ± 7.8 at weeks 4,8, 12 respectively; in Group C are132.2 ± 9.2, 114.8 ± 8.6, 89.9 ± 9.1 at weeks 4,8, 12 respectively. \* *P* \< 0.05-Weeks 4, 8,12 versus week 0 in groups A, B, and C. Intergroup comparison of FPG levels at weeks 4,8 and 12: At weeks 4, 8, and12- (^\#^*P* \< 0.05-Groups B, C vs. Group A), (^\#\#^*P* \< 0.05-Groups C vs. Group B). Statistical test used was analysis of variance followed by Tukey\'s honestly significant difference test](IJPharm-46-24-g003){#F2}

![Changes in postprandial plasma glucose (PPPG) level (mg/ dL) in groups A, B, and C. PPPG level (mean± SD) in Group A are 210.5 ± 8.5, 195.8 ± 9.3, 178.5 ± 9.1 at weeks 4, 8, 12 respectively; in Group B are 191.7 ± 9.9, 177.8 ± 11.2, 157.2 ± 10.9 at weeks 4,8, 12 respectively; in Group C are 173.2 ± 9.4, 156.9 ± 8.5, 135.7 ± 8.3 at weeks 4,8, 12 respectively. \**P* \< 0.05-Weeks 4, 8, and 12 versus week 0 in groups A, B, and C. Intergroup comparison of PPPG levels at weeks 4, 8, and 12: At weeks 4, 8, and 12- (^\#^*P* \< 0.05-Groups B, C vs. Group A), (^\#\#^*P* \< 0.05-Groups C vs. Group B.) Statistical test used was analysis of variance followed by Tukey\'s honestly significant difference test](IJPharm-46-24-g004){#F3}

![Changes in glycosylated hemoglobin (HbA1C) level (%) in groups A, B, and C. HbA1C level (mean ± SD) in groups A, B and C are 7.55 ± 0.59, 7.03 ± 0.61, 6.6 ± 0.65 respectively at week 12.\* *P* \< 0.05- Week 12 versus week 0 in groups A, B, and C-intra-group comparison by paired *t* test. At week 12:^\#^*P* \< 0.05-Groups B, C, versus Group A-inter group comparison by analysis of variance followed by Tukey\'s honestly significant difference test](IJPharm-46-24-g005){#F4}

Safety analysis was carried out as per ITT analysis. All patients who were randomized were considered for safety analysis. Total nine patients developed AEs. The most common AEs are nausea and vomiting. None of the patients in group A reported any AE. Three patients (12%) in group B reported nausea and vomiting. Six patients (23%) in group C reported dizziness and vomiting. These AEs were noted during initiation of therapy and they were mild to moderate in nature. These lasted for about 2 weeks. Two patients (8%) in group B and three patients (12%) in group C were withdrawn from the study due to AEs. Causality analysis showed that they were in the "possible" category. Causality analysis of AE was done as per the WHO-UMC criteria.([@ref8])

Discussion {#sec1-4}
==========

Despite availability of several oral ADAs, pharmacotherapy of type 2 DM is far from satisfactory. Hence, there is always need for newer therapeutic targets and newer drugs. Bromocriptine is a dopamine type 2 (D~2~)-receptor agonist that has been approved for the treatment of type 2 DM. Based on animal and human studies, timed bromocriptine administration within 2 h of awakening is believed to augment low hypothalamic dopamine levels and inhibit excessive sympathetic tone within the CNS. This results in decrease in plasma glucose levels due to suppression of hepatic glucose production.\[[@ref9]\]

Data from our study suggest metformin alone and in combination with bromocriptine in escalating dose (0.8 mg and 1.6 mg/day) significantly decreased FPG and PPPG levels at weeks 4, 8, and 12 compared with their respective baseline values. HbA~1C~ level in all three treatment groups significantly decreased at week 12 from their respective baseline value. Add on therapy of bromocriptine with metformin compared to metformin alone significantly decreased FPG and PPPG levels in a dose-dependent manner. At week 12, HbA~1C~ level in groups B and C significantly decreased compared with group A. There was no statistically significant change in weight from baseline in any of the study groups suggesting weight neutrality of bromocriptine. However, the duration of present study was only 12 weeks.

There are few clinical trials evaluated efficacy and safety of bromocriptine in type 2 DM. In a small study of 12 nondiabetic obese hyperinsulinemic (≥20 μU/mL) subjects, bromocriptine (1.6 mg/day for 2 weeks) reduced the fasting and postprandial (standardized meals) glucose levels without change in body weight.\[[@ref9][@ref10]\] In all studies, bromocriptine was administered in the morning within 2 h of awaking. These studies included: 24-week monotherapy trial\[[@ref11]\], two 24-week add-on to sulfonylurea trials\[[@ref12]\] and 52-week add-on to various oral ADAs trial.\[[@ref13]\] Results of these studies consistently demonstrated a placebo-subtracted decline in HbA~1C~ of 0.5%-0.7%. Efficacy data also are available from a large 52-week randomized, double-blind, placebo-controlled trial in which bromocriptine was added to therapy in poorly controlled (HbA~1C~ \> 7.5%) type 2 diabetic patients who were taking one to two oral ADAs.\[[@ref14]\] In type 2 diabetic subjects who completed 24 weeks of treatment and who took ≥80% of their medication, the placebo-subtracted decrease in HbA~1C~ ranged from 0.6% to 0.9% and was consistent in subjects failing any oral ADA, or their combinations.\[[@ref10][@ref14][@ref15]\] Data from our study are also in agreement with these studies.

Safety analysis of our studies shows incidence nausea, vomiting, and dizziness in few patients on bromocriptine. These AEs were mild to moderate in nature. Although 8% patients in group B and 12% patients in group C necessitate drug withdrawal, there was no reported case of serious life-threatening AE.

Conclusion {#sec1-5}
==========

The results of this randomized, open-labeled phase IV clinical trial showed that add on therapy of bromocriptine with metformin is more effective compared with metformin alone in a dose-dependent manner. This add-on therapy is also safe.
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